Skip to main content
Premium Trial:

Request an Annual Quote

Applied Spectral Imaging, Kromatid Ink Global Comarketing Pact for FISH Probes

NEW YORK – Applied Spectral Imaging (ASI) and Kromatid said on Tuesday they have entered into a strategic partnership.

Under the terms of the agreement, ASI obtained worldwide rights to market Kromatid's Pinpoint fluorescence in situ hybridization (PPF) probes and assay services, used to study genomic structural variants, alongside its Genasis imaging platform.

"ASI's imaging and analysis platform Genasis will provide automation, advanced algorithms, and image analysis capabilities to realize the full potential of the PPF technology" ASI CEO Limor Shiposh said in a statement.

"Kromatid will provide probes for common oncology and rare disease targets, as well as work with any researcher or clinical lab using ASI's powerful imaging platform to develop the highest resolution FISH assays available in the industry," Kromatid CCO David Sebasta added.

Financial and other details of the deal were not disclosed.

Longmont, Colorado-based Kromatid signed a codevelopment deal with Empire Genomics in 2017 and last year won a two-year grant from the National Human Genome Research Institute to advance its single-cell structural genomics technology into disease research.

Carlsbad, California-based ASI offers diagnostic systems for use in pathology and cytogenetics. It has offices in the US and Asia. The firm signed a comarketing agreement with Agilent in 2016.